5Ralston SH, Thiebaud D, Herrmann Z, et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcemia. Br J Cancer, 1997,75 (2) : 295-300.
3[1]Seidman AD,Tiersten A,Hudis C,et al. Phase Ⅱtrial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer[J].J Clin Oncol, 1995,13(10):2 575.
4[5]Robert N,Leyland-Jones B, Asmar L,et al. Phase Ⅲ comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer[J].Breast Cancer Res Treat, 2002,76(supple): 37.
5[6]Seidman AD, Fornier MN, Esteva FJ,et al.Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification[J].J Clin Oncol,2001,19(10):2 587.
6[7]Henderson C,Berry DA,Demetri GD,et al. Improved outcomes form adding sequential paclitaxel but not form escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer[J]. J Clin Oncol,2003,21 (6): 976.
7[8]Nabholtz JM,Pienkowski T,Mackey J,et al. Phase Ⅲ trial comparing TAC (docetaxel, doxorubicin,cyclophosphamide) with FAC (5-fluorouracil,doxorubicin,cyclophospha-mide) in the adjuvant treatment of node positive breast cancer(BC)patients: interim analysis of the BCIRG 001 study[A].ASCO, 2002,21:141 abstr.
8[9]Pirker R, Krajnik G, Zochbauer S, et al. Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC) [J].Ann Oncol, 1995,6(8):833.
9[12]van Oosterom AT.Docetaxel(taxotere) and gemcitabine phase Ⅰ and early phase Ⅱ studies: results to date and an overview of ongoing studies[J].Semin Oncol, 1999,26(3 suppl 11): 8.
10[15]Fossella FV,Belani CP.Phase Ⅲ study(TAX 326)of docetaxel-cisplatin and docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin(VC) for the firstline treatment of advanced/metastatic non-smallcell lung cancer(NSCLC):analyses in elderly patients[A].ASCO,2003, 22:2 528 abstr.
